全文获取类型
收费全文 | 39478篇 |
免费 | 5633篇 |
国内免费 | 892篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 419篇 |
妇产科学 | 349篇 |
基础医学 | 4310篇 |
口腔科学 | 450篇 |
临床医学 | 3484篇 |
内科学 | 1153篇 |
皮肤病学 | 149篇 |
神经病学 | 319篇 |
特种医学 | 2215篇 |
外国民族医学 | 74篇 |
外科学 | 5208篇 |
综合类 | 5222篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 1946篇 |
眼科学 | 67篇 |
药学 | 2135篇 |
32篇 | |
中国医学 | 672篇 |
肿瘤学 | 17734篇 |
出版年
2024年 | 148篇 |
2023年 | 691篇 |
2022年 | 1471篇 |
2021年 | 2064篇 |
2020年 | 1907篇 |
2019年 | 1641篇 |
2018年 | 1514篇 |
2017年 | 1563篇 |
2016年 | 1738篇 |
2015年 | 2111篇 |
2014年 | 2620篇 |
2013年 | 2838篇 |
2012年 | 2239篇 |
2011年 | 2386篇 |
2010年 | 1819篇 |
2009年 | 1772篇 |
2008年 | 1733篇 |
2007年 | 1852篇 |
2006年 | 1877篇 |
2005年 | 1700篇 |
2004年 | 1401篇 |
2003年 | 1340篇 |
2002年 | 1087篇 |
2001年 | 966篇 |
2000年 | 765篇 |
1999年 | 676篇 |
1998年 | 540篇 |
1997年 | 515篇 |
1996年 | 420篇 |
1995年 | 363篇 |
1994年 | 272篇 |
1993年 | 232篇 |
1992年 | 212篇 |
1991年 | 200篇 |
1990年 | 143篇 |
1989年 | 128篇 |
1988年 | 130篇 |
1987年 | 115篇 |
1986年 | 108篇 |
1985年 | 144篇 |
1984年 | 106篇 |
1983年 | 74篇 |
1982年 | 86篇 |
1981年 | 84篇 |
1980年 | 43篇 |
1979年 | 48篇 |
1978年 | 36篇 |
1977年 | 28篇 |
1976年 | 26篇 |
1973年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
23.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
24.
目的:研究乳腺癌细胞中转录调节因子c-Myb的表达对肺转移的影响及其分子机制。方法:构建c-Myb高表达的4T1乳腺癌细胞株,种植小鼠构建乳腺癌动物模型,检测实验动物肺转移情况,通过荷瘤抑制试验检测肺转移抑制效果。提取组织进行荧光PCR检测相关炎症因子的表达。利用Medisapiens数据库的生物信息学资源,对c-Myb和Ccl2的表达与乳腺癌患者的预后进行分析。结果:高表达c-Myb的荷瘤小鼠肺部转移灶明显减少,其中炎症相关因子表达受限。由数据库分析得出,c-Myb高表达患者生存期得以延长。结论:乳腺癌中c-Myb的表达能够通过炎症因子Ccl2抑制肺转移从而延长患者生存期。 相似文献
25.
26.
27.
HER2-positive breast cancer is an aggressive subtype identified in the 1980s. The development of therapies targeting the HER2 has improved outcomes. The current standard of care, established in 2012 is dual blockade with trastuzumab + pertuzumab as first-line followed by TDM-1 as second-line. Several suboptimal choices are available in third-line or more. In 2019 the presentation of several trials evaluating new drugs and regimens in third-line has re-opened questions about sequencing, treatment of triple positive disease and treatment choice after exposure to TDM-1. These include tucatinib, neratinib and trastuzumab-deruxtecan. Other agents – including other antibody drug conjugates and bispecific antibodies as well as combinations - will lead to further changes in coming years. Additionally, should the numerous putative biomarkers thus identified ever come into use at the clinic, choice of treatment and response evaluation may be substantially changed. 相似文献
28.
目的:探讨吉西他滨联合西妥昔单抗对三阴乳腺癌细胞增殖、迁移、侵袭的影响,并对可能的机制进行初步的探究。方法:将实验分为西妥昔单抗组(150 μg · mL-1)、吉西他滨联合用药组(西妥昔单抗150 μg · mL-1,吉西他滨2.8 μg·mL-1)。通过MTT、Transwell实验检测联合用药对MDA-MB-231细胞增殖、迁移、侵袭能力的影响,Western blotting实验检测合用药对MDA-MB-231细胞MMP-9、TIMP-1、p-IkB、NF-kB-p65表达水平的影响。结果:吉西他滨联合西妥昔单抗作用MDA-MB-231细胞后,其生长被不同程度的抑制,抑制率随吉西他滨浓度的增加而增高(P<0.05);联合用药组MDA-MB-231细胞迁移、侵袭数目明显减少(P<0.05),同时MMP-9、p-IkB、NF-kB-p65的表达含量降低,TIMP-1表达含量增加。结论:吉西他滨联合西妥昔单抗对三阴乳腺癌细胞增殖、侵袭、迁移具有抑制作用,并明显抑制MMP-9的表达,其机制可能是通过抑制NF-kB通路实现。 相似文献
29.
目的 探讨中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对三阴性乳腺癌的临床预后影响及与Ki - 67表达的关系。方法 回顾性分析2006年1月 - 2012年12月于我院乳腺外科住院治疗的134例三阴性乳腺癌患者。NLR最佳临床分界值采用ROC曲线确定,并依此分NLR<2.64组和NLR≥2.64组。临床独立预后因素采用单因素和多因素Cox回归模型分析。术后生存时间和生存曲线比较采用Kaplan - Meier和log - rank方法。Ki - 67的表达采用免疫组织化学方法检测。结果 NLR是三阴性乳腺癌的独立预后因素,最佳临界值为2.64。NLR<2.64组术后中位DFS为39.10月,中位OS为52.30月;NLR≥2.64组术后中位DFS为27.35月,中位OS为37.35月。2组术后DFS和OS比较,差异具有统计学意义(P<0.05)。NLR低组伴Ki - 67表达阴性的三阴性患者术后中位DFS和OS生存时间显著高于其他情况。结论 NLR是三阴性乳腺癌的关键影响预后因素,具有重复性强、非侵袭性、方便实用等特性,可用于预测三阴性乳腺癌临床预后。 相似文献
30.